
The chairman, chief executive officer, and cofounder of Ocugen discussed programs including OCU400 and OCU410.
The chairman, chief executive officer, and cofounder of Ocugen discussed programs including OCU400 and OCU410.
The chairman, chief executive officer, and cofounder of Ocugen discussed the recent data update on the company’s OCU400 program in inherited retinal diseases.
The chairman, chief executive officer, and cofounder of Ocugen discussed unmet needs within retinitis pigmentosa and the potential of OCU400 gene therapy.
Published: August 16th 2024 | Updated: August 19th 2024
Published: March 18th 2024 | Updated: June 3rd 2024
Published: December 7th 2024 | Updated:
Published: December 12th 2022 | Updated:
Published: July 14th 2024 | Updated:
Published: May 18th 2023 | Updated: